Cancer Cellular Therapy Research Group

The Cancer Cellular Therapy Research Group aims to develop advanced research in cellular therapy. In this approach, lymphocytes are isolated from the patient’s peripheral blood and undergo genetic engineering or in vitro manipulation to increase their tumor specificity and anti-tumor activity. The cellular products are then safely infused back into the patient. Currently, we have focused on the development of adoptive NK cell therapy for high risk acute myeloid leukemia and chimeric antigen receptor (CAR) T cells.

Focus Areas

The current works of our research group are focused on the development of CAR T cells using a non-viral based method. We have collaborated with Nagoya University to develop a clinical-grade CAR-CD19 T cell therapy for hematologic malignancies using the PiggyBac transposon system. Additionally, our research aims to improve the function of CAR T cells against solid tumors, particularly breast and ovarian cancers, using genetic engineering strategies.

Contact